Angiopoietin-2 as a biomarker for metabolic syndrome and disease activity in rheumatoid arthritis patients

Abstract

BackgroundThe incidence of metabolic syndrome (MetS) increases in rheumatoid arthritis (RA) patients which increases the risk of cardiovascular disease (CVD). Angiopoietin-2 levels increase in RA and were reported to predict CVD. Aim of the workTo assess the level of angiopoietin-2 in RA patients and study its relation to disease activity and its role in those with MetS. Patients and methodsThe study included 80 RA patients (67 females and 13 males) and 20 healthy age and sex matched controls. The patients were divided into Group 1 (n=40) with MetS and Group 2 (n=40) without. Data were collected throughout history, basic clinical examination and investigation. Disease activity score (DAS-28) was assessed in all patients. Enzyme linked immunosorbent assay was used for the estimation of angiopoietin-2. ResultsThe age and disease duration of those with MetS (40.7±7.23years and 9.63±6.73years respectively) and those without (38.6±9.2 and 8.65±5.52years respectively) were comparable (p=0.26 and p=0.48 respectively). The disease activity (DAS-28) was also similar in both groups (5.12±0.77 and 5.01±0.96 respectively; p=0.56). There was a significant increase in the angiopoietin-2 levels in RA patients with MetS (5.31±0.56ng/ml) than those without (4.93±0.44ng/ml) (p<0.001). The levels were significantly higher than those of the control (4.44±0.29ng/ml) (p<0.001). The angiopoietin-2 level significantly correlated with the DAS-28 (r=0.23, p=0.045), systolic (r=0.36, p=0.001) and diastolic blood pressure (r=0.35, p=0.001), fasting blood sugar (r=0.29, p=0.009) and triglycerides (r=0.24, p=0.03). ConclusionsAngiopoietin-2 can be used as a biomarker of MetS and disease activity in RA patients. This could point to those RA patients at risk of developing CVDs.